If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFevertree Regulatory News (FEVR)

Share Price Information for Fevertree (FEVR)

Share Price is delayed by 15 minutes
Get Live Data
781.00    -19.00 (-2.38%)
Bid:
784.00
Ask:
786.50
Spread: 2.50 (0.319%)
Market Cap: £883.40m
FEVR Live PriceLast checked at - London Stock Exchange

Intraday Fevertree Share Chart

Pre-close trading update

29 Jan 2026 07:00

RNS Number : 8094Q
Fevertree Drinks PLC
29 January 2026
 

Fever-Tree Drinks plc

"Excellent strategic progress in 2025 and expect to deliver a financial performance

marginally ahead of market expectations."

 

Fever-Tree Drinks plc (the "Group"), the world's leading supplier of premium carbonated mixers, today provides a pre-close trading update for the year ended 31 December 2025.

 

Adjusted revenue1 and adjusted EBITDA2 for FY25 are expected to be marginally ahead of current market expectations3, based upon good momentum in the second half which has resulted in Fever-Tree brand revenue increasing by 5% in H2, and full year growth of 4% (both at constant currency). This reflects continued delivery against the Group's strategic priorities and ongoing strong market share performance. In the US, the transition into Molson Coors' national distribution network is progressing to plan and, alongside an upweighted marketing investment, will provide a strong platform for 2026.

 

Following the £100m share buyback programme undertaken during 2025, the previously announced additional £30m share buyback tranche will commence in February 2026.

 

£m

FY25

£m

FY24

£m

% change

 

% change (CC)*

US

131.9

128.0

3%

6%

UK

108.4

111.1

(2%)

Europe Fever-Tree brand revenue

94.7

92.7

2%

2%

ROW

37.7

32.2

17%

22%

Total Adjusted Fever-Tree Revenue1

372.7

364.0

2%

4%

GDP brand revenue

2.6

4.5

(42%)

(43%)

Total Adjusted Revenue

375.3

368.5

2%

3%

*Constant Currency (CC).1. Adjusted Revenue is statutory reported revenue adjusted to bring US revenue in line with invoiced sales to customers.2. Adjusted EBITDA is earnings before interest, tax, depreciation, amortisation, share-based payment charges, exceptional items and finance costs. As disclosed in September 2025, the Company has not provided for certain costs related to UK Extended Producer Responsibility levy, and continues to engage with the Environment Agency on the same.3. Company collated consensus FY25 adjusted revenue £372.4m and adjusted EBITDA £44.4m. FY26 adjusted revenue consensus £409.4m (current range £392.4m to £429.0m)) and adjusted EBITDA consensus £49.9m (current range £43.7m to £53.8m)

2025 Highlights:

· US revenue +6%*. The integration of Fever-Tree into Molson Coors' national network of distributors has progressed well through the year, with continued positive brand momentum.

· UK revenue -2%. Trading notably improved in the second half, driven by a robust Off-Trade performance with increasing momentum across the Group's portfolio beyond tonic, particularly our premium soft drink range.

· Europe revenue +2%*. Growth was led by a strong performance in France and Benelux, as the Group continued to execute its strategy across the region.

· ROW +22%* reflecting particularly strong growth in Australia, New Zealand and Canada as well as some beneficial phasing of orders.

 

Outlook

We remain comfortable with current 2026 market expectations.

Tim Warrillow, CEO of Fever-Tree commented:

"We made excellent progress in 2025. Our partnership with Molson Coors in the US is progressing well, and the momentum behind the brand is especially encouraging, giving us confidence in the growing opportunity in our largest market as execution moves beyond the transition phase.

Across all our markets, we are continuing to build momentum as we broaden Fever-Tree beyond tonic, positioning the brand as not only the premium mixer but also premium soft drink of choice. We are uniquely positioned to unlock the growth opportunities afforded by the consumer trends towards moderation, premiumisation and longer, lighter serves. With exciting marketing campaigns and a strong innovation pipeline, delivered by our passionate team, I am confident we will drive strong growth in 2026 and beyond."

Next Scheduled Announcement

The Group will announce its Preliminary Results on 24 March 2026.

 

For more information please contact:

Investor queries

Steve Nightingale, Investor Relations Director I steve.nightingale@fever-tree.com I +44 (0)7951 849 564

Media queries

Oliver Winters, Director of Communications I oliver.winters@fever-tree.com I +44 (0)770 332 9024

 

Nominated Advisor and Broker - Investec Bank plc

David Flin I +44 (0)20 7597 5970

Corporate Broker - Jefferies International Limited

Ed Matthews I +44 (0)20 7029 8000

Financial PR advisers - FGS Global

Faeth Birch +44 (0)7768 943 171; Anjali Unnikrishnan +44 (0) 7826 534 233

 

 

Notes to the Editors:

Fever-Tree is the world's leading supplier of premium carbonated mixers by retail sales value, with distribution to over 95 countries worldwide. Based in the UK, the brand was launched in 2005 to provide high quality mixers which could cater to the growing demand for premium spirits, in particular gin, but also increasingly for vodka, rum and whisky. The Company now sells a range of carbonated mixers and soft drinks to hotels, restaurants, bars and cafes ("On Trade") as well as a broad range of retail outlets ("Off Trade").

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFLFLALRITFIR
Date   Source Headline
28th Sep 20236:20 pmRNSHolding(s) in Company
14th Sep 202312:18 pmRNSDirector/PDMR Shareholding
12th Sep 20236:25 pmRNSFever-Tree FY23 Interim Results - Replacement
12th Sep 20237:00 amRNSFever-Tree FY23 Interim Results
1st Aug 20232:16 pmRNSTotal Voting Rights
3rd Jul 20234:00 pmRNSTotal Voting Rights
1st Jun 20237:00 amRNSBlock Listing Return
1st Jun 20237:00 amRNSTotal Voting Rights
25th May 20231:54 pmRNSResult of AGM
25th May 20237:00 amRNSBoard Changes
25th May 20237:00 amRNSAGM Trading Statement
12th May 202311:25 amRNSHolding(s) in Company
5th May 20237:00 amRNSGrant of Options
2nd May 20237:00 amRNSTotal Voting Rights
21st Apr 20231:08 pmRNSNotice of AGM
22nd Mar 20237:00 amRNSFY22 Preliminary Results to 31 December 2022
8th Mar 20239:49 amRNSHolding(s) in Company
8th Feb 20232:56 pmRNSStandard form for notification of major holdings
30th Jan 20234:32 pmRNSHolding(s) in Company
26th Jan 20237:00 amRNSFY22 pre-close trading update
17th Jan 20239:45 amRNSStandard form for notification of major holdings
19th Dec 20227:00 amRNSBlock Admission Application
12th Dec 20227:00 amRNSDomenic De Lorenzo to succeed Bill Ronald as Chair
1st Dec 20229:00 amRNSBlock Listing Return
21st Nov 20227:00 amRNSChange Of Nominated Advisor and Corporate Broker
15th Nov 20226:18 pmRNSStandard form for notification of major holdings
1st Nov 20227:00 amRNSTotal Voting Rights
17th Oct 20223:09 pmRNSStandard form for notification of major holdings
4th Oct 202210:25 amRNSDirector/PDMR Shareholding
3rd Oct 20229:00 amRNSDirector/PDMR Shareholding
13th Sep 20227:00 amRNSFever-Tree FY22 Interim Results
1st Sep 20227:00 amRNSTotal Voting Rights
24th Aug 202212:06 pmRNSStandard form for notification of major holdings
19th Jul 20229:57 amRNSDirector/PDMR Shareholding
18th Jul 20227:00 amRNSDirector/PDMR Shareholding
15th Jul 20224:00 pmRNSDirector/PDMR Shareholding
15th Jul 202210:14 amRNSDirector/PDMR Shareholding
15th Jul 20227:00 amRNSHY pre-close trading update
1st Jul 20222:26 pmRNSFever Tree drinks plc Total Voting Rights
29th Jun 20227:00 amRNSStandard form for notification of major holdings
10th Jun 20228:45 amRNSNOTIFICATION OF MAJOR HOLDINGS
1st Jun 20227:00 amRNSDirector/PDMR Shareholding
1st Jun 20227:00 amRNSTotal Voting Rights
31st May 20227:00 amRNSBlock Listing Return
23rd May 20223:00 pmRNSDirector/PDMR Shareholding
19th May 202212:57 pmRNSResult of Annual General Meeting
19th May 20227:00 amRNSTrading Update
3rd May 20227:00 amRNSRetirement of Chair of the Board
28th Apr 20224:00 pmRNSGrant of Options
21st Apr 20225:00 pmRNSStandard form for notification of major holdings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.